• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
WANG Yuanyuan,JIANG Lingling,LI Shutong,KONG Liang,YAN Jie,LIU Zhen,XU Baoli.Prescription optimization and evaluation of in vitro targeting effects of liver cancer stem cell niche responsive multistep targeting liposomes[J].Journal Of Pharmaceutical Research,2024,43(10):937-942,947[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2893times   Download 2698次 QR Code for this article
Scan with your phone!
肝癌干细胞niche响应型逐级靶向脂质体处方优选及体外靶向作用评价
王媛媛1,姜玲玲1,李淑彤2,孔亮2,闫洁1,刘震1,徐保利1
Font:Larger+|Default|Smaller-
(1.大连大学附属中山医院药剂科,辽宁 大连 116001;2.辽宁中医药大学药学院,辽宁 大连 116600)
摘要:
目的 制备负载多柔比星(DOX)和XAV-939的肝癌干细胞niche响应型逐级靶向脂质体(CAP@CD133-D/X-Lip),并初步评价其体外靶向作用。方法采用薄膜分散-硫酸铵梯度法制备CAP@CD133-D/X-Lip。通过Box-Behnken设计-响应面法确定CAP@CD133-D/X-Lip的最优处方制备工艺;通过加入纤维细胞活化蛋白(FAP-a)与脂质体反应测定粒径变化考察CAP@CD133-D/X-Lip中两亲肽(CAP)的敏感性;通过细胞摄取实验考察不同制剂对肝癌干细胞(LCSCs)的体外靶向能力。结果最优处方工艺为EPC 44 mg、Chol 2 mg、XAV-939 0.156 mg、DOX 1.16 mg、DSPE-PEG2000 2 mg、DSPE-PEG2000-MAL 2 mg、DSPE-PEG2000-CAP-PEG2000-UAMC1110 2 mg,超声功率为500 W,总处方量为5 mL,两药平均包封率为79.79%±0.89%;加入重组FAP-α蛋白后CAP@CD133-D/X-Lip的平均粒径缩小至(95.56±2.32)nm,显示出CAP@CD133-D/X-Lip具有较好的微环境响应能力;细胞摄取实验显示,相比于CAP@CD133-D/X-Lip,CAP@CD133-D/X-Lip+FAP-α有着更强的摄取能力,说明其靶向LCSCs的能力明显增强。结论本研究成功制备了CAP响应型逐级靶向LCSCs的脂质体,且其具有良好的微环境响应与体外靶向能力。
关键词:  脂质体  多柔比星  响应面法  肝癌干细胞
DOI:10.13506/j.cnki.jpr.2024.10.001
基金项目:国家自然科学基金项目(No.82204629);辽宁省科技厅博士启动基金项目(No.2022-BS-197);大连大学附属中山医院博士启动课题(No.DLDXZSYY-BK201903);大连大学学科交叉项目(No.DLUXK-2023-YB-006)
Publication Date:October 30, 2024
Prescription optimization and evaluation of in vitro targeting effects of liver cancer stem cell niche responsive multistep targeting liposomes
WANG Yuanyuan1,JIANG Lingling1,LI Shutong2,KONG Liang2,YAN Jie1,LIU Zhen1,XU Baoli1
(1.Department of Pharmacy, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001,China; 2.School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600,China)
Abstract:
Objective To prepare liver cancer stem cell niche responsive multistep targeting liposome loaded with doxorubicin (DOX) and XAV-939(CAP@CD133-D/X-Lip), and to evaluate its targeting effect in vitro. Methods Thin film dispersion-ammonium sulfate gradient method was used to prepare CAP@CD133-D/X-Lip. The optimal prescription and preparation process were optimized by Box-Behnken response surface method. The sensitivity of amphipathic peptides (CAP) in CAP@CD133-D/X-Lip was evaluated by determining the particle size changes of liposomes through adding fibroblast activation protein (FAP-a). The in vitro targeting ability of different formulations to liver cancer stem cells (LCSCs) was investigated by cell uptake assay. Results The optimal formulation process was EPC 44 mg, Chol 2 mg, XAV-939 0.156 mg, DOX 1.16 mg, DSPE-PEG2000 2 mg, DSPE-PEG2000-MAL 2 mg, DSPE-PEG2000-CAP-PEG2000-UAMC1110 2 mg, ultrasound power was 500 W, total prescription volume was 5 mL, and the average encapsulation efficiency of the two drugs was 79.79%±0.89%. The average particle size of CAP@CD133-D/X-Lip reduced to (95.56±2.32) nm after the addition of recombinant FAP-α protein, indicating that CAP@CD133-D/X-Lip had an excellent microenvironment response. The cell uptake experiment showed that CAP@CD133-D/X-Lip+FAP-α had a stronger uptake ability than CAP@CD133-D/X-Lip, indicating that its ability to target LCSCs was significantly enhanced. Conclusions CAP-responsive multistep targeting liposomes to LCSCs are successfully prepared, and they have good microenvironment response and in vitro targeting ability.
Key words:  Liposomes  Doxorubicin  Response surface method  Liver cancer stem cells
Today's Visits:487    Total Visits:2383201
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.